Gómez Martín, Carlos
Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen. [artículo] - Clinical & translational oncology, 2012 - 14(9):689-97.
Formato Vancouver:
Gómez-Martin C, Sánchez A, Irigoyen A, Llorente B, Pérez B, Serrano R, et al. Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen. Clin Transl Oncol. 2012 Sep;14(9):689-97.
PMID: 22855151
Contiene 27 referencias
Hand-foot syndrome (HFS) is a limiting toxicity of capecitabine, which is not life-threatening but could compromise capecitabine efficacy.
Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen. [artículo] - Clinical & translational oncology, 2012 - 14(9):689-97.
Formato Vancouver:
Gómez-Martin C, Sánchez A, Irigoyen A, Llorente B, Pérez B, Serrano R, et al. Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen. Clin Transl Oncol. 2012 Sep;14(9):689-97.
PMID: 22855151
Contiene 27 referencias
Hand-foot syndrome (HFS) is a limiting toxicity of capecitabine, which is not life-threatening but could compromise capecitabine efficacy.
